FreeTCCL Archive Abraxane-Gemcitabine Combination Extends Overall Survival in Phase III Trial A phase III trial of Abraxane extended overall survival in metastatic pancreatic cancer, with some patients surviving longer than three years, when used in combination with gemcitabine.February 03, 2014Vol.37 No.01
